FilingReader Intelligence
Marksans Pharma surpasses ₹2,000 crore revenue milestone
July 16, 2025 at 10:30 AM UTC•By FilingReader AI
Marksans Pharma Limited reported record revenue of ₹2,623 crore for 2024-25, driven by 35% year-on-year growth in the US market. The company's OTC business surpassed ₹2,000 crore revenue.
EBITDA margin reached 20.2% with net margin of 14.2%. The company is expanding capacity at its Goa facility to handle 8 billion units annually.
Marksans targets ₹3,000 crore revenue over the next two years.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:MARKSANS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Marksans Pharma publishes news
Free account required • Unsubscribe anytime